Fremanezumab-Vfrm
Brand name: Ajovy Autoinjector
Rank #385 of 500 drugs by total cost
$24.7M
Total Cost
29,389
Total Claims
$24.7M
Total Cost
1,325
Prescribers
$840
Cost per Claim
1,056
Beneficiaries
35,311
30-Day Fills
$19K
Avg Cost/Provider
22
Avg Claims/Provider
About Fremanezumab-Vfrm
Fremanezumab-Vfrm (sold as Ajovy Autoinjector) was prescribed 29,389 times by 1,325 Medicare Part D providers in 2023, costing the program $24.7M. At $840 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 382 | Glimepiride (Glimepiride) | $25.3M | 1,885,737 |
| 383 | Flecainide Acetate (Flecainide Acetate) | $25.1M | 412,334 |
| 384 | Pioglitazone Hcl (Pioglitazone Hcl) | $24.8M | 1,182,614 |
| 385 | Fremanezumab-Vfrm (Ajovy Autoinjector) | $24.7M | 29,389 |
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology